降尿酸防痛风饮治疗痰浊阻滞型慢性迁延期痛风性关节炎合并高脂血症患者30例的疗效及安全性观察  

Efficacy and Safety of Jiangniaosuan Fangtongfeng Drink in the Treatment of 30 Patients with Chronic Refractory Gouty Arthritis(Turbid Phlegm Obstruction)Complicated with Hyperlipidemia

作　　者：曾志威 陈洪 黄桂琼 ZENG Zhi-wei;CHEN Hong;HUANG Gui-qiong(Department of General Internal Medicine,Huizhou Hospital of Guangzhou University of Chinese Medicine,Huizhou Guangdong 516000;Department of Internal Medicine,Huizhou Hospital of Guangzhou University of Chinese Medicine,Huizhou Guangdong 516000;Department of Respiratory Medicine,Huizhou Hospital of Guangzhou University of Chinese Medicine,Huizhou Guangdong 516000)

机构地区：[1]广州中医药大学惠州医院,广东惠州516000 [2]广州中医药大学惠州医院大内科,广东惠州516000 [3]广州中医药大学惠州医院呼吸科,广东惠州516000

出　　处：《世界中西医结合杂志》2024年第2期379-383,共5页World Journal of Integrated Traditional and Western Medicine

基　　金：广东省中医药局科研项目(20173016)。

摘　　要：目的 观察降尿酸防痛风饮治疗痰浊阻滞型慢性迁延期痛风性关节炎合并高脂血症患者30例的疗效及安全性。方法 选取2021年12月—2022年12月期间就诊于广州中医药大学惠州医院的慢性迁延期痛风性关节炎合并高脂血症患者60例作为研究对象,按随机数字表法分为西药组和综合组,每组各30例。西药组予美洛昔康片治疗,综合组在西药组基础上联合降尿酸防痛风饮治疗。治疗28 d后,观察比较两组患者临床疗效、不良反应情况,治疗前后中医证候积分、关节疼痛视觉模拟量表(Visual analogue scale, VAS)评分、血尿酸(Blood uric acid, BUA)、C反应蛋白(C-reaction protein, CRP)、红细胞沉降率(Erythrocyte sedimentation rate, ESR)、总胆固醇(Triglycerides, TC)、甘油三酯(Triglycerides, TG)水平。结果 治疗后综合组临床总有效率93.33%(28/30)明显高于西药组70.00%(21/30),差异有统计学意义(P<0.05)。治疗14、28 d后,两组患者中医证候积分、关节疼痛VAS评分较治疗前降低,差异有统计学意义(P<0.05);且综合组中医证候积分、关节疼痛VAS评分均明显低于西药组,差异有统计学意义(P<0.05);两组患者治疗28 d后中医证候积分、关节疼痛VAS评分均明显低于治疗14 d后,差异有统计学意义(P<0.05)。治疗14、28 d后,两组患者BUA水平均较治疗前降低,差异有统计学意义(P<0.05);且综合组BUA水平明显低于西药组,差异有统计学意义(P<0.05)。两组患者治疗28 d后BUA水平均低于治疗14 d后,差异有统计学意义(P<0.05)。治疗28 d后,两组患者CRP、ESR、TC、TG水平均较治疗前降低,差异有统计学意义(P<0.05);且综合组CRP、ESR、TC、TG水平明显低于西药组,差异有统计学意义(P<0.05)。治疗期间,两组患者不良反应发生率比较,差异无统计学意义(χ^(2)=1.071,P=0.301)。结论 降尿酸防痛风饮可改善慢性迁延期痛风性关节炎(痰浊阻滞)合并高脂血症患者临床症状、治疗Objective To assess the efficacy and safety of Jiangniaosuan Fangtongfeng Drink in the treatment of 30 patients with chronic refractory gouty arthritis characterized by turbid phlegm obstruction,complicated with hyperlipidemia.Methods Sixty patients with chronic refractory gouty arthritis and hyperlipidemia who were treated at Huizhou Hospital of Guangzhou University of Chinese Medicine from December 2021 to December 2022 were enrolled as study subjects.They were divided into a Western medicine group and a combination group by a random number table,with 30 in each group.The Western medicine group received meloxicam tablets,while the combination group received Jiangniaosuan Fangtongfeng Drink in addition to Western medicine.After 28 days of treatment,clinical efficacy,adverse reactions,traditional Chinese medicine(TCM)syndrome scores,visual analogue scale(VAS)scores,blood uric acid(BUA),C-reactive protein(CRP),erythrocyte sedimentation rate(ESR),total cholesterol(TC),and triglycerides(TG)before and after treatment were compared between the two groups.Results The combination group showed a higher total effective rate of 93.33%(28/30)compared with the Western medicine group of 70.00%(21/30)(P<0.05).After 14 and 28 days of treatment,the TCM syndrome scores and VAS scores decreased in both groups compared with the conditions before treatment(P<0.05),and the combination group had lower scores than the Western medicine group(P<0.05).Additionally,the BUA level in both groups decreased after treatment(P<0.05),with the combination group showing a greater reduction than the Western medicine group(P<0.05),and the BUA after 28 days of treatment was lower than that after 14 days of treatment(P<0.05).Both groups had down-regulated CRP,ESR,TC,and TG levels after 28 days of treatment(P<0.05),with the combination group having lower levels than the Western medicine group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(χ^(2)=1.071,P=0.301).Conclusion Jiangniaosuan Fangtongfen

关 键 词：慢性迁延期痛风性关节炎 高脂血症 降尿酸防痛风饮 血尿酸 总胆固醇 安全性 

分 类 号：R593[医药卫生—内科学] R684.3[医药卫生—临床医学]